Pharmacy technicians working at a Virginia health care facility paid more than $2 million to work on an $8.7 million drug trial for Pfizer’s cholesterol-lowering drug Avandia, a state health official said Tuesday.
The money was for “preclinical testing” to help determine whether Avandiala could treat the disease, said Dr. David G. Zangane, the executive director of the Commonwealth of Virginia.
The state health department will determine the cost of the trial, he said.
Pfizer has said Avandias cholesterol-reducing properties are likely to be of clinical value in the near future.
The deal was announced by Health and Human Services Secretary Seema Verma, and a Pfizer spokeswoman said the company is committed to working with the VA.